Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
Chemical and physical data | |
Formula | C14H18FNO |
Molar mass | 235.302 g·mol−1 |
3D model (JSmol) | |
| |
|
2F-NENDCK (CanKet, 2-Fluoro-N-Ethylnordeschloroketamine, 2'-Fluoro-2-Oxo-Phenylcyclohexylethylamine, 2'-Fluoro-2-Oxo-PCE) is a recreational designer drug from the arylcyclohexylamine family, with dissociative effects presumably similar to those of ketamine. Its general effects, dissociative or otherwise, may deviate from other arylcyclohexylamines, however, with one recreational user reporting it felt "very similar to ketamine, but not as deep or introspective". [1]
It was initially identified in Canberra, Australia in mid-August 2022 by the government-funded drug-testing service CanTEST. [2] It has since been dubbed "CanKet" due to it originally being found in Canberra and being a structural analogue of ketamine. [3] [4] It has subsequently been discovered in Taiwan, China and New Zealand. [5] [6] [7]
Due to the lack of research pertaining to it, there are no known legitimate uses for CanKet. Its long-term effects on the human body are unknown, and therefore, it is generally advised for individuals to refrain from consuming CanKet, as is the case for most other designer drugs.
While not much is known about the drug's effects, anecdotal reports offer some insight into them. According to a VICE News interview with one anonymous recreational user,
"it’s worse [than ketamine] but only slightly… The ‘happy’ feeling was lacking a little bit. I find I snort K [ ketamine] and a smile forms on my face when it starts kicking in. This was lacking that—I’d just come up and kinda stay in a mundane headspace while feeling wonky." [1]
On online forums, users report conflicting information about its effects, with some users reporting a stimulating effect. [8] Most agree that the duration of its effects is four to six hours, [8] much longer than ketamine's duration, which typically is approximately one hour when insufflated. [9]
While such anecdotal reports may shed some light on CanKet's effects, it is important to note that these are highly subjective, and individual differences may lead to different users experiencing different effects. Professor Malcom MacLeod, an associate professor at the Australian National University's research school of chemistry, while speaking on the topic of CanKet, stated, "We don't know much about its effects," observing that users' accounts of the effects vary and are "often quite subjective and [it can be] a bit hard to unravel exactly what’s going on." [1]
Chemically, CanKet is a fluorinated arylcyclohexylamine and a ketamine derivative. It is quite similar to ketamine structurally but differs in a few ways:
Ketamine is a dissociative anesthetic used medically for induction and maintenance of anesthesia. It is also used as a treatment for depression and in pain management. Ketamine is an NMDA receptor antagonist which accounts for most of its psychoactive effects.
Phencyclidine or phenylcyclohexyl piperidine (PCP), also known in its use as a street drug as angel dust among other names, is a dissociative anesthetic mainly used recreationally for its significant mind-altering effects. PCP may cause hallucinations, distorted perceptions of sounds, and violent behavior. As a recreational drug, it is typically smoked, but may be taken by mouth, snorted, or injected. It may also be mixed with cannabis or tobacco.
Dissociatives, colloquially dissos, are a subclass of hallucinogens that distort perception of sight and sound and produce feelings of detachment – dissociation – from the environment and/or self. Although many kinds of drugs are capable of such action, dissociatives are unique in that they do so in such a way that they produce hallucinogenic effects, which may include dissociation, a general decrease in sensory experience, hallucinations, dream-like states or anesthesia. Despite most dissociatives' main mechanism of action being tied to NMDA receptor antagonism, some of these substances, which are nonselective in action and affect the dopamine and/or opioid systems, may be capable of inducing more direct and repeatable euphoria or symptoms which are more akin to the effects of typical "hard drugs" or common drugs of abuse. This is likely why dissociatives are considered to be addictive with a fair to moderate potential for abuse, unlike psychedelics. Despite some dissociatives, such as phencyclidine (PCP) possessing stimulating properties, most dissociatives seem to have a general depressant effect and can produce sedation, respiratory depression, nausea, disorientation, analgesia, anesthesia, ataxia, cognitive and memory impairment as well as amnesia.
K-hole is the feeling of getting a high enough dose of ketamine to experience a state of dissociation. This intense detachment from reality is often a consequence of accidental overconsumption of ketamine; however, some users consciously seek out the k-hole as they find the powerful dissociative effects to be quite pleasurable and enlightening. Regardless of the subjective experiences of k-holing, there are many psychological and physical risks associated with such high levels of ketamine consumption.
Arylcyclohexylamines, also known as arylcyclohexamines or arylcyclohexanamines, are a chemical class of pharmaceutical, designer, and experimental drugs.
3-Methoxyphencyclidine (3-MeO-PCP) is a dissociative hallucinogen of the arylcyclohexylamine class related to phencyclidine (PCP) which has been sold online as a designer drug. It has been used across Europe and the United States. In some cases, consumption has been known to be fatal. It acts mainly as an NMDA receptor antagonist, though it has also been found to interact with the sigma σ1 receptor and the serotonin transporter. The drug does not possess any opioid activity nor does it act as a dopamine reuptake inhibitor.
4-Methoxyphencyclidine is a dissociative anesthetic drug that has been sold online as a research chemical. The synthesis of 4-MeO-PCP was first reported in 1965 by the Parke-Davis medicinal chemist Victor Maddox. A 1999 review published by a chemist using the pseudonym John Q. Beagle suggested the potency of 4-MeO-PCP in man was reduced relative to PCP, two years later Beagle published a detailed description of the synthesis and qualitative effects of 4-MeO-PCP, which he said possessed 70% the potency of PCP. 4-MeO-PCP was the first arylcyclohexylamine research chemical to be sold online, it was introduced in late 2008 by a company trading under the name CBAY and was followed by several related compounds such as 3-MeO-PCP and methoxetamine. 4-MeO-PCP has lower affinity for the NMDA receptor than PCP, but higher affinity than ketamine, it is orally active in a dosage range similar to ketamine, with some users requiring doses in excess of 100 mg for desired effects. Users have reported substantial differences in active dose, these discrepancies can be partially explained by the presence of unreacted PCC and other impurities in samples sold on the grey market. 4-MeO-PCP has Ki values of 404 nM for the NMDA receptor, 713 nM for the norepinephrine transporter, 844 nM for the serotonin transporter, 296 nM for the σ1 receptor and 143 nM for the σ2 receptor.
Methoxetamine (MXE) is a dissociative hallucinogen that has been sold as a designer drug. It differs from many dissociatives such as ketamine and phencyclidine (PCP) that were developed as pharmaceutical drugs for use as general anesthetics in that it was designed specifically to increase the antidepressant effects of ketamine.
Methoxyketamine or 2-MeO-2-deschloroketamine is a designer drug of the arylcyclohexylamine class first reported in 1963. It is an analog of ketamine in which the chlorine atom has been replaced with a methoxy group. Its synthesis by rearrangement of an amino ketone has been reported. As an arylcyclohexylamine, methoxyketamine most likely functions as an NMDA receptor antagonist. It produces sedative, hallucinogenic, and anesthetic effects, but with a lower potency than ketamine itself.
3-Methoxyeticyclidine (3-MeO-PCE), also known as methoxieticyclidine, is a dissociative anesthetic that is qualitatively similar to PCE and PCP and has been sold online as a designer drug.
2-Fluorodeschloroketamine is a dissociative anesthetic related to ketamine. Its sale and use as a designer drug has been reported in various countries. It is an analogue of ketamine where the chlorine group has been replaced by fluorine. Due to its recent emergence, the pharmacological specifics of the compound are mostly unclear, but effects are reported to be similar to its parent compound, ketamine.
2-Oxo-PCE is a dissociative anesthetic of the arylcyclohexylamine class that is closely related to deschloroketamine and eticyclidine, and has been sold online as a designer drug.
2-Bromodeschloroketamine is a chemical compound of the arylcyclohexylamine class, which is an analog of the dissociative anesthetic drug ketamine in which the chlorine atom has been replaced with a bromine atom. It is used in scientific research as a comparison or control compound in studies into the metabolism of ketamine and norketamine, and has also been sold online alongside arylcyclohexylamine designer drugs, though it is unclear whether bromoketamine has similar pharmacological activity.
MXiPr is a recreational designer drug with dissociative effects. It is an arylcyclohexylamine derivative, related to drugs such as ketamine and methoxetamine. It was first identified in Slovenia in December 2020, and was made illegal in Hungary in April 2021.
3-Fluoro-PCP is a recreational designer drug from the arylcyclohexylamine family, with dissociative effects. It was first identified in Slovenia in October 2020, and was made illegal in Hungary in April 2021.
4-Keto-PCP is a recreational designer drug from the arylcyclohexylamine family, with dissociative effects. It has potency in between that of ketamine and phencyclidine but with somewhat more sedating effects in animal studies.
3-Fluorodeschloroketamine is a recreational designer drug related to ketamine. It is from the arylcyclohexylamine family and has dissociative effects. It was made illegal in Finland in August 2019.
Fluorexetamine is a recreational designer drug from the arylcyclohexylamine family, with dissociative effects. It has reportedly been sold over the internet since around 2017, though has remained relatively uncommon.
Hydroxetamine is a recreational designer drug from the arylcyclohexylamine family, with dissociative effects. It is known as an active metabolite of the dissociative designer drug methoxetamine, but has also been sold in its own right since late 2019.